This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Gisbert JP et al. (2008) Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients. Aliment Pharmacol Ther 27: 346–354
Malfertheiner P et al. (2007) Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56: 772–781
Bazzoli F et al. (1998). Evaluation of short low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study. Aliment Pharmacol Ther 12: 439–445
Neri M et al. (2003) Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments. Aliment Pharmacol Ther 18: 821–827
Romano M et al. (2003) Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helicobacter pylori. Clin Gastroenterol Hepatol 1: 273–278
Toracchio S et al. (2000). Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. Aliment Pharmacol Ther 14: 1639–1643
Lamouliatte H et al. (2003) Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. Aliment Pharmacol Ther 18: 791–797
Miwa H et al. (2003) Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection? Aliment Pharmacol Ther 17: 1545–1551
Gomollon F et al. (2000) Third line treatment for Helicobacter pylori: a prospective, culture-guided study in peptic ulcer patients. Aliment Pharmacol Ther 14: 1335–1338
Cammarota G et al. (2004) High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. Aliment Pharmacol Ther 19: 789–795
Fischbach LA et al. (2004) Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther 20: 1071–1082
Megraud F (2004) H. pylori antibiotic resistance: prevalence, importance and advances in testing. Gut 53: 1374–1384
Gisbert JP et al. (2006) Third-line rescue therapy with levofloxacin after two H. pylori treatment failures. Am J Gastroenterol 101: 243–247
Zullo A et al. (2003). A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication. Dig Liver Dis 35: 232–236
Perna F et al. (2007) Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance. Dig Liver Dis 39: 1001–1005
Carothers JJ et al. (2007) The relationship between previous fluoroquinolone use and levofloxacin resistance in Helicobacter pylori infection. Clin Infect Dis 44: 5–8
Gisbert JP et al. (2006) Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Aliment Pharmacol Ther 24: 1469–1474
Fakheri H et al. (2001) Clarithromycin versus furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. Aliment Pharmacol Ther 15: 411–416
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Fuccio, L., Zagari, R. & Bazzoli, F. What is the best salvage therapy for patients with Helicobacter pylori infection?. Nat Rev Gastroenterol Hepatol 5, 608–609 (2008). https://doi.org/10.1038/ncpgasthep1256
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpgasthep1256